Biocompatibility of dialysis fluid for online HDF.
We investigated the effects of online hemodiafiltration (HDF) using acetate-free bicarbonate dialysis (AFD) fluid on bioincompatibility as represented by inflammatory markers in patients undergoing maintenance hemodialysis therapy and compared it with conventional acetate-containing bicarbonate dialysis (ACD) fluid. A total of 24 maintenance hemodialysis patients were registered for cross-over design during the 6-month study period (13 males and 11 females, aged 58.2 ± 14.5 years, mean duration of dialysis 10.0 ± 8.0 years, chronic glomerular nephritis in 20 patients, diabetic nephropathy in 2 patients, polycystic kidney in 1 patient, and nephrosclerosis in 1 patient). These patients were subjected to ACD for the first 3 months followed by AFD fluid for the latter 3 months. Blood variables of C-reactive protein and interleukin-6 were determined after each of the first and latter 3-month periods. The filters (membrane surface area, raw material), the conditions of HDF (blood flow rate, dialysate flow rate, dialysis time, dry weight, pre-dilution mode and convective volume) and drug regimen including erythrocyte-simulating agent (drug type, dosage) were unchanged throughout the cross-over study. There appeared to be significantly higher levels of predialysis blood pH and bicarbonate in the AFD phase than in the ACD phase. Blood C-reactive protein and interleukin-6 levels were significantly decreased in AFD group as compared with those seen in ACD group. From these results, it can be suggested that online HDF using AFD fluid contributes to alleviating microinflammation, a prognostic factor for bioincompatible events in hemodialysis patients.